96 results
SC TO-I
EX-99
CYDY
CytoDyn Inc.
3 Jun 24
Issuer tender offer statement
5:10pm
a further negative effect on the market price of our common stock.
-16-
We are subject to oversight by the SEC, FDA, and other regulatory agencies … .
We are subject to the regulation and oversight by the SEC and state regulatory agencies, in addition to the FDA and other federal regulatory agencies
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:16pm
of oversight and controls. The consolidated complaint also asserts claims against one or more individual defendants for waste of corporate assets, unjust … and misleading statements and by failing to maintain an adequate system of oversight and controls. The
complaint also asserts claims against certain
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:15pm
of oversight and controls. The consolidated complaint also asserts claims against one or more individual defendants for waste of corporate assets, unjust … and misleading statements and by failing to maintain an adequate system of oversight and controls. The
complaint also asserts claims against certain
424B3
vduur3ot359s4anc36
19 Jan 24
Prospectus supplement
5:15pm
424B3
ayppcn5w1 3fyx321
24 Oct 23
Prospectus supplement
6:01am
424B3
m240z7bx3aj0ie
10 Oct 23
Prospectus supplement
6:02pm
POS AM
hnzs0 idl
2 Oct 23
Prospectus update (post-effective amendment)
5:15pm
NT 10-K
g8x07kw4vloo2q
30 Aug 23
Notice of late annual filing
5:15pm
424B3
hxeypbsqyd4l7
11 Jul 23
Prospectus supplement
5:28pm
8-K
EX-99.1
5mge4lw
28 Oct 22
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
5:15pm